



## Notes for using the data:

- The data are calculated from the antibiotic sales in each prefecture of Japan.
- The data do not always reflect the actual use of antibiotics in healthcare settings.
- The data based on only the sales of antibiotics for use in humans and do not include the sales of antibiotics for use in animals or for addition to feed.
- The definition of antibiotic drugs is taken from J01 of the ATC classification published by the WHO (i.e., oral metronidazole, which belongs to P01, is not included).
- The figures indicate drug utilization standardized by defined daily dose (DDD) per population and drug, called DID (DDDs/1,000 inhabitants/day).
- The DDD is according to data published on January 1, 2017.
- The population is according to estimates on October 1 of every year published by the Statistics Bureau, Ministry of Internal Affairs and Communications.
- The population size was updated in 2021; thus, it was different from that published in February 2022.
- 0.000 indicates a value less than 0.001.


Change in Antimicrobial Consumption in Japan (2013-2021) by ATC3



Change in Antimicrobial Consumption in Japan (2013-2021) by route of administration




Change in Antimicrobial Consumption in Japan (2013-2021) by AWaRe Classification



## Change in Antimicrobial Consumption in Japan (2013-2021) by ATC4

### Outcome indices for Oral antimicrobials in National Action Plan on Antimicrobial Resistance



※This slide shows only oral antimicrobials by ATC4 in National Action Plan on Antimicrobial Resistance Outcome Indicators. Therefore, the values are different from the second slide.